復星醫藥(02196.HK)擬認購聯合健康險9722萬股新增股份
格隆匯5月5日丨復星醫藥(02196.HK)發佈公吿,公司擬與順德科創集團共計出資人民幣49,776.64萬元參與認購聯合健康險合計19,444萬股新增發行股份(對應新增註冊資本人民幣19,444萬元),其中:公司擬出資人民幣24,888.32萬元認購聯合健康險9,722萬股新增股份(對應新增註冊資本人民幣9,722萬元)。本次增資完成後,本公司將持有聯合健康險約14.00%的股權。
聯合健康險成立於2017年1月,註冊地為廣東省廣州市,法定代表人為曾明光先生。聯合健康險是國內第六家專業健康險公司,已設有北京、上海、江蘇、四川、重慶5家分公司以及6家中心支公司和1家支公司,覆蓋國內經濟水平較發達、居民生活水平較高、保險消費需求較高的四大核心經濟圈(粵港澳大灣區、長三角、京津冀、成渝)。聯合健康險的保險業務包括各類醫療保險、疾病保險、失能收入損失保險、護理保險和意外保險;截至本公吿日,已累計向市場推出160餘款特色保險產品和健康管理服務,打造了保險+醫療、保險+醫藥等特色產品(如針對罹患乳腺癌風險保障的“乳果愛醫療保險”、面向中等收入家庭的中端醫療保險),並搭建了包括健康體檢、診療服務、藥品供給、健康管理在內的服務網絡,國內合作的醫療及健康服務機構超過1,000家;在聚焦健康保險供給、深耕專業健康保險賽道的同時,聯合健康險積極探索商業模式創新,通過打造線上線下融合、核心生態融合的O2O一體化管理式健康服務平台,開發了健康保險產品和健康管理服務深度融合的高端醫療保障方案。
本次增資所得款項擬用於聯合健康險補充資本金,以提高償付能力和承保能力,並進一步擴大業務規模。本次增資將有利於推動本集團醫藥、醫療健康服務等業務與商業保險的合作融通,進一步探索模式創新、加深業務協同。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.